Corvia Medical taps PhysIQ for remote monitoring in interatrial shunt study

Corvia Medical said it launched a heart failure device trial that will include the collection and analysis of data with PhysIQ’s continuous remote monitoring platform.

The Phase III trial is designed to evaluate the efficacy of Tewksbury, Mass.-based Corvia’s interatrial shunt in patients with heart failure. The randomized, controlled, double-blinded study includes plans to provide patients with a wearable biosensor and mobile data hub to establish a personalized pre-intervention baseline prior to randomization, then for 12 months after implantation.